Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study.
Rheumatology (Oxford)
; 61(3): 1026-1034, 2022 03 02.
Article
in En
| MEDLINE
| ID: mdl-34097014
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Thalidomide
/
Arthritis, Psoriatic
/
Cardiometabolic Risk Factors
Type of study:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Rheumatology (Oxford)
Journal subject:
REUMATOLOGIA
Year:
2022
Document type:
Article
Country of publication:
United kingdom